Aktie A144510 GC CELL CORPORATION
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen GC Cell Corporation

Aktien

A144510

KR7144510005

A144510

Schlusskurs Korea S.E.
Andere Börsenplätze
 00:00:00 05.07.2024 		% 5 Tage % 1. Jan.
30 300 KRW +4,84 % Intraday Chart für GC Cell Corporation +7,45 % -33,41 %
20.06. GC Cell unterzeichnet ein MOU mit PT Bifarma Adiluhung, einer Tochtergesellschaft der Kalbe Group CI
26.02. GC Cell und Biocentriq® schließen Prozess-Transfer-Vereinbarung im Vorgriff auf die Markteinführung von Immuncell-LC Inj in den USA ab CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
GC Cell Signs an MOU with PT Bifarma Adiluhung, an Affiliate of Kalbe Group
GC Cell participates 2024 BIO International Convention, Unveiling its future Blueprint 2.0, as the First Korean Business Forum Sponsor
GC Cell and Biocentriq® Execute Process Transfer Agreement in Anticipation of the U.S. Entry of Immuncell-LC Inj
GC Cell's Promising AB-201 Cancer Treatment to Begin Phase 1 Trials Using Lunit AI Platform
GC Cell Affiliate BioCentriq Secures $29 Million in Funding Round
GC Cell Signs Agreement with Lunit for AI-Powered Cancer Treatment
GC Cell Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023
GC Cell Obtains Anti-Bribery Management System Certification from Korea Compliance Initiative
GC Cell Inks First Licensing Agreement for Immuncell-LC® With Rivaara Immune Private Limited in India
Green Cross Lab Cell Corporation completed the acquisition of Green Cross Cell Corporation from a group of shareholders.
Green Cross Lab Cell Corporation entered into a definitive merger agreement to acquire Green Cross Cell Corporation from a group of shareholders for approximately KRW 510 billion.
Artiva Biotherapeutics, Inc. announced that it has received $120.000001 million in funding from a group of investors
Artiva Biotherapeutics, Inc. announced that it expects to receive $120.000001 million in funding
Artiva Biotherapeutics, Inc. announced that it expects to receive $80.552315 million in funding from 5AM Venture Management, LLC, venBio LLC, RA Capital Management, L.P., Medivate Partners LLC, Green Cross Holdings Corporation, Green Cross Lab Cell Corporation
Kleo Pharmaceuticals Enters into Research Collaboration with Green Cross LabCell to Rapidly Develop COVID-19-Targeting Allogeneic NK Cell Combination Therapy
Green Cross LabCell and Feldan Therapeutics Announce a Joint Research Collaboration to Develop Low Immunogenicity, High-Performance Natural Killer Anticancer Treatment
Green Cross Lab Cell Corporation Announces Executive Changes
Green Cross Lab Cell Corporation(KOSDAQ:A144510) added to S&P Global BMI Index
GreenCross LabCell Corporation has completed an IPO in the amount of KRW 37.00 billion.
Oxford BioMedica plc Enters into Research & Development Collaboration with Green Cross LabCell
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A144510 Aktie
  4. Nachrichten GC Cell Corporation
  5. Andere Sprachen